MRD Outcomes From CEPHEUS at ASH 2024

January 10, 2025

Saad Z. Usmani, MD, MBA, FACP

Opinion

Video

Saad Z. Usmani, MD, MBA, FACP, discusses how the CEPHEUS study, presented at ASH 2024, along with its expanded analysis of minimal residual disease (MRD) outcomes, provides valuable insights into the role of MRD as a biomarker in multiple myeloma treatment, highlighting its potential to guide therapy decisions and improve patient outcomes.

EP: 1.Early Intervention in High-Risk Smoldering Myeloma: Results From the AQUILA Study at ASH 2024

EP: 2.Exploring the Frontline Potential of Teclistamab: Insights From MajesTEC-5 at ASH 2024

Now Viewing

EP: 3.MRD Outcomes From CEPHEUS at ASH 2024

EP: 4.Transplant-Ineligible Myeloma and MRD Integration: Current Definitions and Future Directions

EP: 5.Anitocabtagene Autoleucel in Focus: Insights From the iMMagine-1 Trial at ASH 2024

EP: 6.Advancing Multiple Myeloma Care: Insights From ASH 2024 and Beyond

Video content above is prompted by the following:

Provide a brief overview of the CEPHEUS study and the expanded analysis of MRD outcomes presented at ASH 2024.
What was the objective of this study?
How was this study designed/what methodology was used?
What additional MRD outcomes were presented?

Related Content

ICYMI: Highlights From AMCP Nexus 2024

December 26th 2024

Article

Check out this year's top coverage from The Academy of Managed Care Pharmacy (AMCP) Nexus 2024 meeting, which included relevant topics in health care policy, novel pharmaceutical developments, financial considerations across multiple conditions, and more.

ICYMI: Highlights From ASCO 2024

December 21st 2024

Article

Top coverage from the 2024 American Society of Clinical Oncology (ASCO) annual meeting included research topics in non-small cell lung cancer (NSCLC), multiple myeloma, metastatic colorectal cancer (mCRC), and more.

ICYMI: Highlights From SLEEP 2024

December 18th 2024

Article

Check out our top 5 most-viewed pieces of coverage from the 2024 SLEEP meeting.

ICYMI: Highlights From ACTRIMS 2024

December 12th 2024

Article

Read about the diverse array of research presented at this year's meeting, including novel technological advancements and insights into disease progression in multiple sclerosis (MS).